Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | THRB | P10828 | 2/20 | 0.58 |
| ▸ | RECQL | P46063 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21154593 | 0.94 | MAPT (0.71) | ALDH1A1KCNH3GAARAB9ATDP1 | |
| SCHEMBL10077132 | 0.94 | ALDH1A1 (0.55) | ALDH1A1KCNH3GAARAB9ATDP1 | |
| SCHEMBL254581 | 0.88 | APP (0.53) | ALDH1A1KCNH3GAARAB9ATDP1 | |
| SCHEMBL3141547 | 0.86 | ALDH1A1 (0.60) | ALDH1A1KCNH3GAARAB9ATDP1 | |
| SCHEMBL20987178 | 0.85 | GAA (0.52) | ALDH1A1KCNH3GAARAB9ATDP1 | |
| SCHEMBL3530110 | 0.83 | TDP1 (0.54) | ALDH1A1KCNH3TDP1MAPTL3MBTL1 | |
| SCHEMBL21153231 | 0.82 | MAPT (0.58) | ALDH1A1GAAMAPTL3MBTL1KDM4E | |
| SCHEMBL20987124 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KCNH3GAARAB9ATDP1 | |
| SCHEMBL20131116 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KCNH3GAARAB9ATDP1 | |
| SCHEMBL28615334 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KCNH3GAARAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007016190-A2 | ANTIPARKINSONIAN ACTION OF PHENYLISOPROPYLAMINES | DUKE UNIVERSITY (US) | 2007-02-08 | — | — | WO | claimed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | claimed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | AMGEN INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| EP-0756602-A1 | CCK OR GASTRIN MODULATING 5-HETEROCYCLIC-1,5-BENZODIAZEPINES | GLAXO WELLCOME INC. (US) | 1997-02-05 | — | — | EP | disclosed |
| EP-0755394-A1 | A METHOD OF INDUCING CHOLECYSTOKININ AGONIST ACTIVITY USING 1,4-BENZODIAZEPINE COMPOUNDS | GLAXO WELLCOME INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0694039-A1 | 1,5-BENZODIAZEPINE DERIVATIVES HAVING CCK ANTAGONISTIC OR AGONISTIC ACTIVITY | GLAXO WELLCOME INC. (US) | 1996-01-31 | — | — | EP | disclosed |
| WO-1995028399-A1 | A METHOD OF INDUCING CHOLECYSTOKININ AGONIST ACTIVITY USING 1,4-BENZODIAZEPINE COMPOUNDS | GLAXO WELLCOME INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| WO-1995028419-A1 | CCK OR GASTRIN MODULATING 5-HETEROCYCLIC-1,5-BENZODIAZEPINES | GLAXO WELLCOME INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| WO-1994024149-A1 | 1,5-BENZODIAZEPINE DERIVATIVES HAVING CCK ANTAGONISTIC OR AGONISTIC ACTIVITY | GLAXO INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| EP-0404146-A2 | Enantiomeric enrichment and stereoselective synthesis of chiral amines | CELGENE CORPORATION (US) | 1990-12-27 | — | — | EP | disclosed |
| US-4161474-A | STABILIZERS, ANTIOZONANTS FOR VULCANIZABLE DIENE RUBBERS | MONSANTO COMPANY (US) | 1979-07-17 | — | — | US | disclosed |
| US-4000197-A | FROM PHENYLACETONES AND METHYL BENZYLAMINE, REDUCTION, HYDROGENOLYSIS | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | ALDH1A1 2642/4885KCNH3 4281/4885GAA 997/4885 |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | ALDH1A1 926/4885KCNH3 479/4885GAA 59/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | ALDH1A1 2427/4885KCNH3 4381/4885GAA 1048/4885 |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | MCL1, BAK1, BCL2A1 | ALDH1A1 393/4885KCNH3 2450/4885GAA 3203/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | ALDH1A1 2642/4885KCNH3 4281/4885GAA 997/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | ALDH1A1 2427/4885KCNH3 4381/4885GAA 1048/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | ALDH1A1 2427/4885KCNH3 4381/4885GAA 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.